{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:53:43Z","timestamp":1773726823091,"version":"3.50.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["orthopedic.theclinics.com","mdconsult.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Orthopedic Clinics of North America"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ocl.2014.03.006","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T08:30:25Z","timestamp":1403857825000},"page":"403-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Use of Bisphosphonates in Orthopedic Surgery"],"prefix":"10.1016","volume":"45","author":[{"given":"Santiago A.","family":"Lozano-Calderon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew W.","family":"Colman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Raskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Hornicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ocl.2014.03.006_bib1","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2106\/JBJS.D.03032","article-title":"Bisphosphonates in orthopaedic surgery","volume":"87","author":"Morris","year":"2005","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib2","first-page":"265","article-title":"Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives","volume":"54","author":"Bisaz","year":"1978","journal-title":"Clin Sci Mol Med"},{"issue":"12","key":"10.1016\/j.ocl.2014.03.006_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2146\/ajhp090506","article-title":"Risks and benefits of long-term bisphosphonate therapy","volume":"67","author":"Schmidt","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.189","article-title":"Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008","volume":"26","author":"Siris","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.ocl.2014.03.006_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.ocl.2014.03.006_bib6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","article-title":"Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis","volume":"33","author":"Amin","year":"1992","journal-title":"J\u00a0Lipid Res"},{"issue":"4","key":"10.1016\/j.ocl.2014.03.006_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in\u00a0vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 6","key":"10.1016\/j.ocl.2014.03.006_bib9","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1242\/jcs.108.6.2285","article-title":"The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts","volume":"108","author":"Zhang","year":"1995","journal-title":"J\u00a0Cell Sci"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.ocl.2014.03.006_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4 Suppl 1","key":"10.1016\/j.ocl.2014.03.006_bib12","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2005.12.020","article-title":"Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?","volume":"119","author":"Bonnick","year":"2006","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.ocl.2014.03.006_bib13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ocl.2014.03.006_bib14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9041","key":"10.1016\/j.ocl.2014.03.006_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ocl.2014.03.006_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ocl.2014.03.006_bib19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ocl.2014.03.006_bib20","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"issue":"24","key":"10.1016\/j.ocl.2014.03.006_bib22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ocl.2014.03.006_bib23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007","volume":"26","author":"Wang","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ocl.2014.03.006_bib25","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/jc.2010-2730","article-title":"Osteoporosis medication and reduced mortality risk in elderly women and men","volume":"96","author":"Center","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11914-010-0009-0","article-title":"Is osteoporosis disease management cost effective?","volume":"8","author":"Dell","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.160.1.77","article-title":"Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"160","author":"Nevitt","year":"2000","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00198-002-1336-5","article-title":"Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years","volume":"14","author":"Newman","year":"2003","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.ocl.2014.03.006_bib29","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00198-010-1444-6","article-title":"Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study","volume":"22","author":"Sambrook","year":"2011","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00198-010-1411-2","article-title":"Oral bisphosphonates are associated with reduced mortality after hip fracture","volume":"22","author":"Beaupre","year":"2011","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib31","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2009-0852","article-title":"Effect of osteoporosis treatment on mortality: a meta-analysis","volume":"95","author":"Bolland","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ocl.2014.03.006_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: a world-wide projection","volume":"2","author":"Cooper","year":"1992","journal-title":"Osteoporos Int"},{"issue":"9","key":"10.1016\/j.ocl.2014.03.006_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s001980200013","article-title":"Treatment of male osteoporosis: recent advances with alendronate","volume":"13","author":"Ringe","year":"2002","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.ocl.2014.03.006_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","article-title":"Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy","volume":"69","author":"Reid","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"10.1016\/j.ocl.2014.03.006_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.ocl.2014.03.006_bib38","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub3","article-title":"Bisphosphonates and other bone agents for breast cancer","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"6 Suppl 21","key":"10.1016\/j.ocl.2014.03.006_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/sonc.2002.37420","article-title":"The antitumor potential of bisphosphonates","volume":"29","author":"Clezardin","year":"2002","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.ocl.2014.03.006_bib42","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.ocl.2014.03.006_bib44","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel","volume":"18","author":"Hillner","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.ocl.2014.03.006_bib45","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ocl.2014.03.006_bib46","first-page":"2324","article-title":"Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate","volume":"83","author":"Rosen","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.ocl.2014.03.006_bib47","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ocl.2014.03.006_bib49","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1359\/jbmr.1998.13.7.1061","article-title":"Paget's disease of bone","volume":"13","author":"Siris","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.ocl.2014.03.006_bib50","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jbmr.5650100421","article-title":"Frequency and characteristics of familial aggregation of Paget's disease of bone","volume":"10","author":"Morales-Piga","year":"1995","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jbmr.5650060511","article-title":"Familial aggregation of Paget's disease of bone","volume":"6","author":"Siris","year":"1991","journal-title":"J\u00a0Bone Miner Res"},{"issue":"183","key":"10.1016\/j.ocl.2014.03.006_bib52","first-page":"303","article-title":"Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone","author":"Mills","year":"1984","journal-title":"Clin Orthop Relat Res"},{"issue":"Suppl","key":"10.1016\/j.ocl.2014.03.006_bib53","first-page":"283","article-title":"Is Paget's disease of bone a viral infection?","volume":"22","author":"Rebel","year":"1977","journal-title":"Calcif Tissue Res"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jbmr.5650090302","article-title":"Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease","volume":"9","author":"Siris","year":"1994","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib55","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 5","key":"10.1016\/j.ocl.2014.03.006_bib56","doi-asserted-by":"crossref","first-page":"493S","DOI":"10.1016\/8756-3282(95)00282-1","article-title":"Tiludronate therapy for Paget's disease of bone","volume":"17","author":"McClung","year":"1995","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.ocl.2014.03.006_bib57","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"issue":"14","key":"10.1016\/j.ocl.2014.03.006_bib58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ocl.2014.03.006_bib59","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/(SICI)1097-4636(199823)43:3<234::AID-JBM3>3.0.CO;2-O","article-title":"Joint fluid from patients with failed total hip arthroplasty stimulates pit formation by mouse osteoclasts on dentin slices","volume":"43","author":"Kim","year":"1998","journal-title":"J\u00a0Biomed Mater Res"},{"issue":"6","key":"10.1016\/j.ocl.2014.03.006_bib61","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00223-002-1022-9","article-title":"Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients","volume":"71","author":"Soininvaara","year":"2002","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"10.1016\/j.ocl.2014.03.006_bib62","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2106\/00004623-200311000-00009","article-title":"The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty","volume":"85","author":"Wang","year":"2003","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"20","key":"10.1016\/j.ocl.2014.03.006_bib63","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2106\/JBJS.J.01646","article-title":"The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial","volume":"93","author":"Skoldenberg","year":"2011","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib64","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1359\/jbmr.2001.16.3.556","article-title":"Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial","volume":"16","author":"Wilkinson","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"issue":"344","key":"10.1016\/j.ocl.2014.03.006_bib65","first-page":"33","article-title":"The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model","author":"Shanbhag","year":"1997","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib66","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2106\/00004623-200202000-00010","article-title":"Alendronate does not inhibit early bone apposition to hydroxyapatite-coated total joint implants: a preliminary study","volume":"84-A","author":"Mochida","year":"2002","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib67","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1067\/mpd.2002.128207","article-title":"Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial","volume":"141","author":"Henderson","year":"2002","journal-title":"J\u00a0Pediatr"},{"issue":"11","key":"10.1016\/j.ocl.2014.03.006_bib68","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0009922812452118","article-title":"Bisphosphonates use in children","volume":"51","author":"Sebestyen","year":"2012","journal-title":"Clin Pediatr"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ocl.2014.03.006_bib70","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00006254-200108000-00023","article-title":"Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature","volume":"56","author":"Kauffman","year":"2001","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00431-004-1541-7","article-title":"Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis","volume":"164","author":"Melchior","year":"2005","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib72","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1210\/jcem-61-5-952","article-title":"Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis","volume":"61","author":"Hoekman","year":"1985","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ocl.2014.03.006_bib73","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJM199108223250804","article-title":"Rapid loss of vertebral mineral density after renal transplantation","volume":"325","author":"Julian","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib74","first-page":"1148","article-title":"A\u00a0metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis","volume":"26","author":"Homik","year":"1999","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib75","first-page":"329","article-title":"Corticosteroid-induced osteoporosis in children: outcome after two-year follow-up, risk factors, densitometric predictive cut-off values for vertebral fractures","volume":"25","author":"Reyes","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.ocl.2014.03.006_bib76","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1469-8749.2010.03676.x","article-title":"Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy","volume":"52","author":"Bachrach","year":"2010","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/adc.71.3.235","article-title":"Osteopenia in cerebral palsy","volume":"71","author":"Shaw","year":"1994","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/PHM.0b013e3181583ddc","article-title":"Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy","volume":"87","author":"Apkon","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/17518420903236270","article-title":"Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions","volume":"13","author":"Howe","year":"2010","journal-title":"Dev Neurorehabil"},{"issue":"1","key":"10.1016\/j.ocl.2014.03.006_bib80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-010-1221-6","article-title":"Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury","volume":"22","author":"Bubbear","year":"2011","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.ocl.2014.03.006_bib81","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1442-200X.2010.03174.x","article-title":"Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease","volume":"52","author":"Sbrocchi","year":"2010","journal-title":"Pediatr Int"},{"issue":"Suppl 3","key":"10.1016\/j.ocl.2014.03.006_bib82","first-page":"929","article-title":"Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome","volume":"15","author":"Matarazzo","year":"2002","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib83","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-001-1098-7","article-title":"Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia","volume":"71","author":"Isaia","year":"2002","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"10.1016\/j.ocl.2014.03.006_bib84","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ocl.2014.03.006_bib85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1651-2227.2000.tb01214.x","article-title":"Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome","volume":"89","author":"Lala","year":"2000","journal-title":"Acta Paediatr"},{"issue":"8903","key":"10.1016\/j.ocl.2014.03.006_bib86","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(94)90069-8","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"343","author":"Liens","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ocl.2014.03.006_bib87","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"382","key":"10.1016\/j.ocl.2014.03.006_bib88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","author":"Lane","year":"2001","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"10.1016\/j.ocl.2014.03.006_bib89","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2106\/JBJS.D.02192","article-title":"Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs","volume":"87","author":"Kim","year":"2005","journal-title":"J Bone Joint Surg Am"},{"issue":"11","key":"10.1016\/j.ocl.2014.03.006_bib90","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1359\/jbmr.2003.18.11.2016","article-title":"Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats","volume":"18","author":"Little","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"issue":"8","key":"10.1016\/j.ocl.2014.03.006_bib91","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"}],"container-title":["Orthopedic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030589814000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030589814000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T11:36:55Z","timestamp":1649504215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030589814000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0030589814000388"],"URL":"https:\/\/doi.org\/10.1016\/j.ocl.2014.03.006","relation":{},"ISSN":["0030-5898"],"issn-type":[{"value":"0030-5898","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Bisphosphonates in Orthopedic Surgery","name":"articletitle","label":"Article Title"},{"value":"Orthopedic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ocl.2014.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}